Biogen Inc. (BIIB – Free Report) , a well-known name in the multiple sclerosis (MS) market, reported mixed fourth-quarter 2016 results with the company surpassing earnings expectations while missing the same for sales. Moreover, the company’s 2017 sales guidance fell short of expectations.

In the past one year, Biogen’s shares declined 0.1%, comparing favourably with the Zacks classified Biomed-Genetics industry’s decline of 9.5%.

Coming back to the results, Biogen reported fourth-quarter 2016 earnings per share of $5.04, beating the Zacks Consensus Estimate of $4.97 by 1.4% and increasing 12% year over year.

Sales came in at $2.87 billion, up 1% from the year-ago period. Sales, however, missed the Zacks Consensus Estimate of $2.95 billion by 2.5%.

Quarter in Detail

Oral multiple sclerosis (MS) drug Tecfidera rose 1% from the year-ago period to $1.0 billion. However, the drug recorded a 3% sequential decline in revenues. This included U.S. sales of $799.7 million and ex-U.S. sales of $202.3 million.

Fourth-quarter Tysabri revenues declined 1% year over year and 8% sequentially to $474 million (U.S. $288.7 million, ex-U.S. $185.2 million).

Combined interferon revenues (Avonex and Plegridy) in the fourth quarter were $688 million (U.S. $488.1 million, ex-U.S. $200.1 million), down 7% from the year-ago period and 3% sequentially. Avonex revenues declined 12% from the year-ago period to $564 million.

Plegridy contributed $125 million to fourth-quarter 2016 revenues, up 21% year over year but down 3% sequentially.

Zinbryta, launched in collaboration with AbbVie Inc. (ABBV – Free Report) in August last year, contributed $6 million to revenues in the quarter compared with $2 million in the third quarter.

Alprolix and Eloctate, Biogen’s hemophilia treatments, recorded revenues of $93 million and $149 million, up 9% and 13%, respectively, year over year.

In the quarter, Biogen recorded biosimilar revenues of $53 million compared with $31 million in the third quarter. Biogen markets Flixabi, a biosimilar referencing Johnson & Johnson’s (JNJ – Free Report) blockbuster drug Remicade and Benepali, a biosimilar referencing Amgen Inc.’s (AMGN – Free Report) Enbrel in Europe.